Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

e its goal of having no more than 5% of

patients lost to follow-up at the time of the week 72

assessment.

ITMN-191:

-- On April 2, InterMune reported top-line results in the four dose

cohorts of treatment-naive patients chronically infected with

hepatitis C virus (HCV) genotype 1 in its Phase 1b multiple-

ascending-dose (MAD) monotherapy trial of ITMN-191:

-- Day 14 median viral kinetic results competitive with those

published for other direct antiviral compounds when used in

monotherapy for 14 days. Specifically, InterMune reported a

median 3.8 log reduction (equal to 99.98% reduction) in HCV RNA

from baseline at Day 14;

-- Significant and rapid viral kinetic activity when dosed every

12 hours; and

-- Excellent safety and tolerability in all dosage regimens.

-- InterMune reported successful completion of 13-week toxicology

studies in rats and monkeys at exposures higher than those expected

to be evaluated in clinical studies. These preclinical studies were

required before initiating the Phase 2 program of ITMN-191 which

will involve durations of therapy longer than those studied in Phase

1.

-- Announced on May 29 the initiation of a 14-day study of ITMN-191 in

combination with Pegasys(R) (pegylated interferon alpha-2a) and

Copegus(R) (ribavirin). The study is proceeding as planned.

-- Submitted several abstracts for possible presentation at the 59th

Annual Meeting of the American Association for the Study of Liver

Diseases (AASLD) to be held October 31 - November 4, 2008 in San

Francisco, including but not limited to data on ITMN-191.

Financial:

-- On June 24, InterMune exchanged $85 million
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Green ... million in Series B funding and secured Otter Capital ... investment capital will accelerate commercialization of GGI’s Agriplier™ technology, ... crop types. , “Since our first meeting, we ... to the biological product space,” said Alan Sobba, President ...
(Date:8/27/2014)... is how plants survive impact by the huge ... while using this energy for photosynthesis. The hypothesis ... blades quickly dissipate the energy throughout the entire ... DTU Physics have now managed to successfully ,film, ... contain light-absorbing proteins which play a role in ...
(Date:8/27/2014)... N.J. , Aug. 27, 2014  A ... potential to help physicians better identify early-stage disease, ... and disability, according to a new study in ... Quest Diagnostics (NYSE: DGX ) and ... the 14-3-3eta protein outperformed conventional antibody-serum testing, including ...
(Date:8/27/2014)... -- Research and Markets has announced the ... Paper Industry Report 2014" report to their offering. ... Paper Industry Report 2014 is a professional and in-depth ... for pulp & paper industry. The report ... classifications, applications and industry chain structure. The enzyme for ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3DTU researchers film protein quake for the first time 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Ala., Jan. 8 BioCryst Pharmaceuticals, Inc. (Nasdaq: ... Chief Executive Officer and Dr. William P. Sheridan, Chief Medical ... J.P. Morgan 27th Annual Healthcare Conference on Thursday, January 15, ... be held January 12-15, 2009 in San Francisco.A link to ...
... DNDN ) today announced that management will present ... Francisco on Thursday, January 15, 2009 at 11:00 a.m. PT. ... be accessible through the Investor Relations section of the Dendreon ... to the live webcast, it will be archived on the ...
... Medical, Inc., the global leader in devices for clot ... has completed a $15 million round of financing. ... New Enterprise Associates, Inc. (NEA) and includes other existing ... the last several months made the opportunity to participate ...
Cached Biology Technology:BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 2BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 3Concentric Medical Closes on $15 Million Financing 2
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... growing number of studies have shown that ... pathogenesis of Parkinson,s disease. Previous studies from ... University in China have shown that baicalin ... reduced divalent metal transporter 1 expression, and ... nigra of rotenone-induced Parkinson,s disease rats. However, ...
(Date:8/27/2014)... the Happy Camp Complex of fires had consumed 24,939 ... had consumed 35,530 as of eight hours ago. ... Camp Ranger District of the Klamath National Forest when ... 2014. All but three of those fires are now ... contained fires and their size at containment: Delta, 150 ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... 2010) The New York Stem Cell Foundation (NYSCF) today ... postdoctoral scientists join 15 accomplished stem cell researchers from leading ... NYSCF has awarded 23 fellowships to date. ... most competitive postdoctoral fellowship programs in the world, has so ...
... year The International Institute for Species Exploration at Arizona State ... previous calendar year. The list for 2009 was published to ... birth of Carl Linnaeus. It contains only two new plant ... Botanical Journal of the Linnean Society . ...
... SPRING HARBOR, N.Y. (Tues., June 1, 2010) -- ... frequently used techniques in RNA analysis. Electrophoresis is ... quality assessment. Gels are involved in a wide ... and analyzing processing reactions. The two most common ...
Cached Biology News:NYSCF awards fellowships to 8 innovative stem cell scientists 2NYSCF awards fellowships to 8 innovative stem cell scientists 3Rare carnivorous plant on top 10 list of newly discovered species 2Electrophoresis of RNA, avian imaging featured in June's Cold Spring Harbor Protocols 2
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
UV-NIR light source for USB2000, HR4000, HR2000+...
Biology Products: